Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City

Kelsie Cowman; Yi Guo; Liise Anne Pirofski; David Wong; Hongkai Bao; Victor Chen; Una Hopkins; Erin Andrews; Joseph Hamel; Marla Keller; Eran Bellin; Raja Thota; Patricia Davis; Edwin Torres Rodriguez; Pooja Suthar; Lauren Allen; James Rossi; Adam Haviland; Erika Orner; Wendy Szymczak; Sadahf Shujauddin; James Mccarthy; Barbara Binder; Vanitha Pushparaj; Linda Bard; Vincent Frank Pierino; Leslie Alsina; David Esses; Alicia Mccaskie; Caron Campbell; Tabitha Madzura; Andrew Wollowitz; Kelly Basset; Deborah J. White; Rafael Ruiz; Frank Sosnowski; Priya Nori

doi:10.1093/ofid/ofab313

Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City

Kelsie Cowman, Yi Guo, Liise Anne Pirofski, David Wong, Hongkai Bao, Victor Chen, Una Hopkins, Erin Andrews, Joseph Hamel, Marla Keller, Eran Bellin, Raja Thota, Patricia Davis, Edwin Torres Rodriguez, Pooja Suthar, Lauren Allen, James Rossi, Adam Haviland, Erika Orner, Wendy SzymczakSadahf Shujauddin, James Mccarthy, Barbara Binder, Vanitha Pushparaj, Linda Bard, Vincent Frank Pierino, Leslie Alsina, David Esses, Alicia Mccaskie, Caron Campbell, Tabitha Madzura, Andrew Wollowitz, Kelly Basset, Deborah J. White, Rafael Ruiz, Frank Sosnowski, Priya Nori

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

We partnered with the US Department of Health and Human Services to treat high-risk, nonadmitted coronavirus disease 2019 (COVID-19) patients with bamlanivimab in the Bronx, New York per Emergency Use Authorization criteria. Increasing posttreatment hospitalizations were observed monthly between December 2020 and March 2021 in parallel to the emergence of severe acute respiratory syndrome coronavirus 2 variants in New York City.

Original language	English (US)
Article number	ofab313
Journal	Open Forum Infectious Diseases
Volume	8
Issue number	8
DOIs	https://doi.org/10.1093/ofid/ofab313
State	Published - Aug 1 2021

Keywords

Antimicrobial stewardship
COVID-19
SARS-CoV-2 variants
monoclonal antibodies

ASJC Scopus subject areas

Oncology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ofid/ofab313

Cite this

Cowman, K., Guo, Y., Pirofski, L. A., Wong, D., Bao, H., Chen, V., Hopkins, U., Andrews, E., Hamel, J., Keller, M., Bellin, E., Thota, R., Davis, P., Rodriguez, E. T., Suthar, P., Allen, L., Rossi, J., Haviland, A., Orner, E., ... Nori, P. (2021). Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City. Open Forum Infectious Diseases, 8(8), Article ofab313. https://doi.org/10.1093/ofid/ofab313

Cowman, K , Guo, Y , Pirofski, LA, Wong, D, Bao, H, Chen, V, Hopkins, U, Andrews, E, Hamel, J, Keller, M , Bellin, E, Thota, R, Davis, P, Rodriguez, ET, Suthar, P, Allen, L, Rossi, J, Haviland, A, Orner, E , Szymczak, W, Shujauddin, S, Mccarthy, J, Binder, B, Pushparaj, V, Bard, L, Pierino, VF, Alsina, L, Esses, D, Mccaskie, A, Campbell, C, Madzura, T, Wollowitz, A, Basset, K, White, DJ , Ruiz, R, Sosnowski, F & Nori, P 2021, 'Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City', Open Forum Infectious Diseases, vol. 8, no. 8, ofab313. https://doi.org/10.1093/ofid/ofab313

@article{42d0cdf736e94d61a918ea020ff5b6e5,

title = "Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City",

abstract = "We partnered with the US Department of Health and Human Services to treat high-risk, nonadmitted coronavirus disease 2019 (COVID-19) patients with bamlanivimab in the Bronx, New York per Emergency Use Authorization criteria. Increasing posttreatment hospitalizations were observed monthly between December 2020 and March 2021 in parallel to the emergence of severe acute respiratory syndrome coronavirus 2 variants in New York City.",

keywords = "Antimicrobial stewardship, COVID-19, SARS-CoV-2 variants, monoclonal antibodies",

author = "Kelsie Cowman and Yi Guo and Pirofski, {Liise Anne} and David Wong and Hongkai Bao and Victor Chen and Una Hopkins and Erin Andrews and Joseph Hamel and Marla Keller and Eran Bellin and Raja Thota and Patricia Davis and Rodriguez, {Edwin Torres} and Pooja Suthar and Lauren Allen and James Rossi and Adam Haviland and Erika Orner and Wendy Szymczak and Sadahf Shujauddin and James Mccarthy and Barbara Binder and Vanitha Pushparaj and Linda Bard and Pierino, {Vincent Frank} and Leslie Alsina and David Esses and Alicia Mccaskie and Caron Campbell and Tabitha Madzura and Andrew Wollowitz and Kelly Basset and White, {Deborah J.} and Rafael Ruiz and Frank Sosnowski and Priya Nori",

note = "Funding Information: L.-a. P. was funded in part by the G. Harold and Leila Y. Mathers Foundation, National Institutes of Health (NIH) Grant R01AI123654, NIH Grant R01AI143453, and National Center for Advancing Translational Sciences Grant 3UL1TR002556-04S1. Y. G., P. N., V. C., and K. C. were funded in part by Merck Grant 59441. Bamlanivimab doses were provided by the US Department of Health and Human Services.*%blankline%* Publisher Copyright: {\textcopyright} 2021 The Author(s).",

year = "2021",

month = aug,

day = "1",

doi = "10.1093/ofid/ofab313",

language = "English (US)",

volume = "8",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City

AU - Cowman, Kelsie

AU - Guo, Yi

AU - Pirofski, Liise Anne

AU - Wong, David

AU - Bao, Hongkai

AU - Chen, Victor

AU - Hopkins, Una

AU - Andrews, Erin

AU - Hamel, Joseph

AU - Keller, Marla

AU - Bellin, Eran

AU - Thota, Raja

AU - Davis, Patricia

AU - Rodriguez, Edwin Torres

AU - Suthar, Pooja

AU - Allen, Lauren

AU - Rossi, James

AU - Haviland, Adam

AU - Orner, Erika

AU - Szymczak, Wendy

AU - Shujauddin, Sadahf

AU - Mccarthy, James

AU - Binder, Barbara

AU - Pushparaj, Vanitha

AU - Bard, Linda

AU - Pierino, Vincent Frank

AU - Alsina, Leslie

AU - Esses, David

AU - Mccaskie, Alicia

AU - Campbell, Caron

AU - Madzura, Tabitha

AU - Wollowitz, Andrew

AU - Basset, Kelly

AU - White, Deborah J.

AU - Ruiz, Rafael

AU - Sosnowski, Frank

AU - Nori, Priya

N1 - Funding Information: L.-a. P. was funded in part by the G. Harold and Leila Y. Mathers Foundation, National Institutes of Health (NIH) Grant R01AI123654, NIH Grant R01AI143453, and National Center for Advancing Translational Sciences Grant 3UL1TR002556-04S1. Y. G., P. N., V. C., and K. C. were funded in part by Merck Grant 59441. Bamlanivimab doses were provided by the US Department of Health and Human Services.*%blankline%* Publisher Copyright: © 2021 The Author(s).

PY - 2021/8/1

Y1 - 2021/8/1

N2 - We partnered with the US Department of Health and Human Services to treat high-risk, nonadmitted coronavirus disease 2019 (COVID-19) patients with bamlanivimab in the Bronx, New York per Emergency Use Authorization criteria. Increasing posttreatment hospitalizations were observed monthly between December 2020 and March 2021 in parallel to the emergence of severe acute respiratory syndrome coronavirus 2 variants in New York City.

AB - We partnered with the US Department of Health and Human Services to treat high-risk, nonadmitted coronavirus disease 2019 (COVID-19) patients with bamlanivimab in the Bronx, New York per Emergency Use Authorization criteria. Increasing posttreatment hospitalizations were observed monthly between December 2020 and March 2021 in parallel to the emergence of severe acute respiratory syndrome coronavirus 2 variants in New York City.

KW - Antimicrobial stewardship

KW - COVID-19

KW - SARS-CoV-2 variants

KW - monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=85118282929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118282929&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofab313

DO - 10.1093/ofid/ofab313

M3 - Article

AN - SCOPUS:85118282929

SN - 2328-8957

VL - 8

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 8

M1 - ofab313

ER -

Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this